Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Everest Medicines Limited
雲頂新耀有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1952)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON THE NEW 100 MG STRENGTH OF XERAVA® APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA

This announcement is made by Everest Medicines Limited (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update.

The board of directors of the Company (the "**Board**") is pleased to announce that National Medical Products Administration (NMPA) of China has approved a new 100 mg strength of XERAVA® (eravacycline hydrochloride for injection). XERAVA® is the world's first and only (as of November 2026) fully synthetic fluorocycline antibiotic. It is indicated for the treatment of complicated intra-abdominal infections ("**cIAI**") in adults and is characterized by a broad antimicrobial spectrum, potent antibacterial activity, confirmed clinical efficacy, and a favorable safety profile. It has been recommended in multiple clinical guidelines as empiric therapy for cIAI and as a clinical option for multidrug-resistant (MDR) infections. The 50 mg strength of XERAVA® was approved in China in 2023 for the treatment of cIAI in adults. The approval of 100 mg strength marks a milestone to further expand the Company's product portfolio and commercial potential, and demonstrates the Company's strong capabilities in advancing product registration to address clinical needs.

The recommended dosage of XERAVA® is 1 mg/kg every 12 hours, based on body weight. The newly approved 100 mg strength offers flexibility in dose preparation, potentially reducing preparation steps and drug wastage for certain patients, while enhancing supply reliability in China.

The Company's Jiashan manufacturing site in China holds the required manufacturing license and is capable of supporting a consistent and reliable product supply. The Company is advancing the localization of XERAVA® manufacturing in China, with technology transfer progressing as planned. Process validation for the 50 mg strength of XERAVA® has been completed. At its Jiashan manufacturing site, the Company continues to expand and upgrade its capabilities, accelerating the local manufacturing of commercialized products, including VELSIPITY® and CARDAMYST®, while advancing API manufacturing to strengthen its integrated production capabilities. These efforts will further strengthen manufacturing capabilities, enhance supply chain stability and resilience, and support the Company's long-term growth.

About XERAVA® (eravacycline hydrochloride for injection)

XERAVA® (eravacycline hydrochloride for injection), is a novel, fully synthetic, fluorocycline intravenous antibiotic for the treatment infections caused by susceptible Gram-positive, Gram-negative and anaerobic pathogens including those multidrug resistant (MDR) isolates.

XERAVA® has been recommended in The Surgical Infection Society Guidelines on the Management of Intra-Abdominal Infection and in multiple global treatment guidelines issued by Infectious Disease Society of America's (IDSA) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) as a treatment choice for multi-drug resistant Gram-negative bacterial infections including Carbapenem resistant organisms. In addition, it was included in an expert consensus on the multi-disciplinary management of intra-abdominal infections by the Chinese Society of Surgery of Chinese Medical Association, Infectious Diseases Society for Evidence-based and Translational Medicine of Chinese Research Hospital Association and the Editorial Board of Chinese Journal of Surgery.

XERAVA® is currently approved for the treatment of cIAI in the United States of America, European Union, United Kingdom, Singapore, the Chinese Mainland and Hong Kong SAR. In March 2023, National Medical Products Administration (NMPA) of China approved New Drug Application (NDA) for XERAVA® for the treatment of cIAI in adult patients. The Company launched XERAVA® in July 2023 in the Chinese Mainland.

By Order of the Board
Everest Medicines Limited
Yifang Wu
Chairman and Executive Director

Hong Kong, 13 November 2026

As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. Xin Sun and Ms. Yue Wang as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.